Summit Therapeutics Inc. (SMMT) fair value analysis
Nasdaq · Updated 2026-10-19
SMMT price how computed
Valuation status
No fair-value estimate yetSMMT has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for SMMT yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $14.63
- Sector
- Healthcare
- 12-month range
- $12.43–$26.38
- Market cap
- $11.7B
- From 52-week high
- -44.5%
- Shares outstanding
- 798M
- Rank in Healthcare by quality score
- #268 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Summit Therapeutics Inc. is a biopharmaceutical company that focuses on developing and commercializing medicines for infectious diseases and other serious conditions. The company operates primarily in the United States and conducts research and development activities in the field of therapeutics.
SMMT currently ranks #268 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $11.7B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-0.90
- Debt / equity
- 0.03
- Shares outstanding
- 798M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 32 · neutral
- 50-day average
- $15.68
- 200-day average
- $16.30
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Last 8 quarters vs consensus
- 1 beat, 6 missed
- Quarter by quarter
- 2026-06 ▼ miss (-7.7%)
2026-03 ▼ miss (-45.2%)
2025-12 ▼ miss (-2000.0%)
2025-09 ▼ miss (-475.0%)
2025-06 ▼ miss (-33.3%)
2025-03 ▲ beat (+0.7%)
2024-12 ▬ met (0.0%)
2024-09 ▼ miss (-20.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 6 hold · 0 sell (17 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $30.2
- Target vs last price
- +106.4%
What our data shows for SMMT
- Shares are trading in the lower third of their 12-month price range of $12.43–$26.38.
- The 14-day relative strength index sits at a neutral 32.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- SMMT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the SMMT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — SMMT's 50/200-day trend state shifted from mixed to downtrend this week, indicating that the stock's shorter-term momentum has weakened relative to its longer-term trajectory. The Healthcare sector company remains classified as awaiting full valuation as TickrTrends continues to gather the necessary data for a complete assessment. This downtrend development may be of interest to investors monitoring the stock's technical positioning.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is SMMT stock undervalued?
TickrTrends has no fair-value estimate for SMMT yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is SMMT's TickrTrends verdict?
SMMT is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does SMMT compare to other Healthcare stocks?
SMMT ranks #268 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is SMMT overbought or oversold?
SMMT's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does SMMT usually beat earnings estimates?
Over its last 8 reported quarters SMMT beat the consensus estimate 1 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SMMT?
Of 17 analysts covering SMMT, 11 rate it a buy, 6 a hold and 0 a sell - buy-leaning, with a consensus price target of $30.2 (+106.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.